{"doi":"10.1002/adtp.202000210","title":"Sulfoglycodendrimer Therapeutics for HIV‐1 and SARS‐CoV‐2","abstract":"Hexavalent sulfoglycodendrimers (SGDs) are synthesized as mimics of host cell heparan sulfate proteoglycans (HSPGs) to inhibit the early stages in viral binding/entry of HIV-1 and SARS-CoV-2. Using an HIV neutralization assay, the most promising of the seven candidates are found to have sub-micromolar anti-HIV activities. Molecular dynamics simulations are separately implemented to investigate how/where the SGDs interacted with both pathogens. The simulations revealed that the SGDs: 1) develop multivalent binding with polybasic regions within and outside of the V3 loop on glycoprotein 120 (gp120) for HIV-1, and consecutively bind with multiple gp120 subunits, and 2) interact with basic amino acids in both the angiotensin-converting enzyme 2 (ACE2) and HSPG binding regions of the Receptor Binding Domain (RBD) from SARS-CoV-2. These results illustrate the considerable potential of SGDs as inhibitors in viral binding/entry of both HIV-1 and SARS-CoV-2 pathogens, leading the way for further development of this class of molecules as broad-spectrum antiviral agents.","journal":"Advanced Therapeutics","year":2021,"id":193691,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9571,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":522693,"name":"Cory Vierra","orcid":null,"position":1,"is_corresponding":false},{"id":762776,"name":"Janee' Michele Hardman","orcid":null,"position":2,"is_corresponding":false},{"id":762239,"name":"Yanxiao Han","orcid":"0000-0002-1684-6073","position":3,"is_corresponding":false},{"id":431400,"name":"Dustin A. Dimas","orcid":null,"position":4,"is_corresponding":false},{"id":762777,"name":"Lucia N. Gwarada‐Phillips","orcid":null,"position":5,"is_corresponding":false},{"id":762778,"name":"Rachel Blackeye","orcid":null,"position":6,"is_corresponding":false},{"id":521970,"name":"Daryl K. Eggers","orcid":"0000-0003-1915-5945","position":7,"is_corresponding":false},{"id":103753,"name":"Celia C. LaBranche","orcid":"0000-0002-6653-6655","position":8,"is_corresponding":false},{"id":762240,"name":"Petr Král","orcid":"0000-0003-2992-9027","position":9,"is_corresponding":false},{"id":521971,"name":"Katherine D. McReynolds","orcid":"0000-0001-8395-3066","position":10,"is_corresponding":false},{"id":762238,"name":"Lauren Wells","orcid":"0000-0002-8404-1007","position":0,"is_corresponding":true}],"reference_count":46,"raw_metadata":null,"created_at":"2026-07-18T23:49:51.300073Z","pmid":"33786368","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}